Thomas A Premeaux

Dr. Thomas A Premeaux

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2021 in Allergy
Verified
Journal Article
Open access
PDF file
MPMatthew Plassmeyer
Matthew Plassmeyer
OAOral Alpan
Oral Alpan
MCMichael J. Corley
Michael J. Corley
TPThomas A Premeaux
Thomas A Premeaux
KLKimberleigh Lillard
Kimberleigh Lillard
RGRaavi Gupta
Raavi Gupta
Background: COVID‐19 can present with lymphopenia and extraordinary complex multiorgan pathologies that can trigger long‐term sequela.Aims: Given that inflammasome products, like caspase‐1, play a role in the pathophysiology of a number of co‐morbid conditions, we investigated caspases across the spectrum of COVID‐19 disease.Materials & Methods: We assessed transcriptional states of multiple caspases and using flow cytometry, the expression of active caspase‐1 in blood cells from COVID‐19 patients in acute and convalescent stages of disease. Non‐COVID‐19 subject presenting with various comorbid conditions served as controls.Results: Single‐cell RNA‐seq data of immune cells from COVID‐19 patients showed a distinct caspase expression pattern in T cells, neutrophils, dendritic cells, and eosinophils compared with controls. Caspase‐1 was upregulated in CD4+ T‐cells from hospitalized COVID‐19 patients compared with unexposed controls. Post‐COVID‐19 patients with lingering symptoms (long‐haulers) also showed upregulated caspase‐1activity in CD4+ T‐cells that ex vivo was attenuated with a select pan‐caspase inhibitor. We observed elevated caspase‐3/7levels in red blood cells from COVID‐19 patients compared with controls that was reduced following caspase inhibition.Discussion: Our preliminary results suggest an exuberant caspase response in COVID‐19 that may facilitate immune‐related pathological processes leading to severe outcomes. Further clinical correlations of caspase expression in different stages of COVID‐19 will be needed.Conclusion: Pan‐caspase inhibition could emerge as a therapeutic strategy to ameliorate or prevent severe COVID‐19.

26 November 2018 in Journal of NeuroVirology
Verified
Journal Article
Closed access
PDF file
TPThomas A Premeaux
Thomas A Premeaux
MDMichelle L. D’aNtoni
Michelle L. D’aNtoni
MAMohamed Abdel-Mohsen
Mohamed Abdel-Mohsen
SPSatish K. Pillai
Satish K. Pillai
KKKalpana J. Kallianpur
Kalpana J. Kallianpur
LNLishomwa Ndhlovu
Lishomwa Ndhlovu

31 October 2023 in mBio
Verified
Journal Article
Open access
PMPreeti Moar
Preeti Moar
TPThomas A Premeaux
Thomas A Premeaux
AAAndrew Atkins
Andrew Atkins
LNLishomwa Ndhlovu
Lishomwa Ndhlovu
Multiple cellular HIV reservoirs in diverse anatomical sites can undergo clonal expansion and persist for years despite suppressive antiretroviral therapy, posing a major barrier toward an HIV cure. Commonly adopted assays to assess HIV reservoir size mainly consist of PCR-based measures of cell-associated total proviral DNA, intact proviruses and transcriptionally competent provirus (viral RNA), flow cytometry and microscopy-based methods to measure translationally competent provirus (viral protein), and quantitative viral outgrowth assay, the gold standard to measure replication-competent provirus; yet no assay alone can provide a comprehensive view of the total HIV reservoir or its dynamics. Furthermore, the detection of extant provirus by these measures does not preclude defects affecting replication competence. An accurate measure of the latent reservoir is essential for evaluating the efficacy of HIV cure strategies. Recent approaches have been developed, which generate proviral sequence data to create a more detailed profile of the latent reservoir. These sequencing approaches are valuable tools to understand the complex multicellular processes in a diverse range of tissues and cell types and have provided insights into the mechanisms of HIV establishment and persistence. These advancements over previous sequencing methods have allowed multiplexing and new assays have emerged, which can document transcriptional activity, chromosome accessibility, and in-depth cellular phenotypes harboring latent HIV, enabling the characterization of rare infected cells across restrictive sites such as the brain. In this manuscript, we provide a review of HIV sequencing-based assays adopted to address challenges in quantifying and characterizing the latent HIV reservoir.

31 August 2021 in mBio
Verified
Journal Article
Open access
TPThomas A Premeaux
Thomas A Premeaux
SMSonia Mediouni
Sonia Mediouni
ALAna Leda
Ana Leda
RFRobert L. Furler
Robert L. Furler
Susana ValenteSusana Valente
Susana Valente
LNLishomwa Ndhlovu
Lishomwa Ndhlovu
Long-term effective use of antiretroviral therapy (ART) among people with HIV (PWH) has significantly reduced the burden of disease, yet a cure for HIV has not been universally achieved, likely due to the persistence of an HIV reservoir. The central nervous system (CNS) is an understudied HIV sanctuary.

6 July 2022 in Psychosomatic Medicine
Verified
Journal Article
Open access
RPRobert Paul
Robert Paul
KCKyu Cho
Kyu Cho
JBJacob Bolzenius
Jacob Bolzenius
CSCarlo Sacdalan
Carlo Sacdalan
LNLishomwa Ndhlovu
Lishomwa Ndhlovu
SSSerena Spudich
Serena Spudich
Objective: We examined individual differences in CD4/CD8 T-cell ratio trajectories and associated risk profiles from acute HIV infection (AHI) through 144 weeks of antiretroviral therapy (ART) using a data-driven approach. Methods: A total of 483 AHI participants began ART during Fiebig I–V and completed follow-up evaluations for 144 weeks. CD4+, CD8+, and CD4/CD8 T-cell ratio trajectories were defined followed by analyses to identify associated risk variables. Results: Participants had a median viral load (VL) of 5.88 copies/ml and CD4/CD8 T-cell ratio of 0.71 at enrollment. After 144 weeks of ART, the median CD4/CD8 T-cell ratio was 1.3. Longitudinal models revealed five CD4/CD8 T-cell ratio subgroups: group 1 (3%) exhibited a ratio >1.0 at all visits; groups 2 (18%) and 3 (29%) exhibited inversion at enrollment, with normalization 4 and 12 weeks after ART, respectively; and groups 4 (31%) and 5 (18%) experienced CD4/CD8 T-cell ratio inversion due to slow CD4+ T-cell recovery (group 4) or high CD8+ T-cell count (group 5). Persistent inversion corresponded to ART onset after Fiebig II, higher VL, soluble CD27 and TIM-3, and lower eosinophil count. Individuals with slow CD4+ T-cell recovery exhibited higher VL, lower white blood cell count, lower basophil percent, and treatment with standard ART, as well as worse mental health and cognition, compared with individuals with high CD8+ T-cell count. Conclusions: Early HIV disease dynamics predict unfavorable CD4/CD8 T-cell ratio outcomes after ART. CD4+ and CD8+ T-cell trajectories contribute to inversion risk and correspond to specific viral, immune, and psychological profiles during AHI. Adjunctive strategies to achieve immune normalization merit consideration.

26 May 2023 in Journal of NeuroVirology
Verified
Journal Article
Closed access
PDF file
TPThomas A Premeaux
Thomas A Premeaux
SYStephen T. Yeung
Stephen T. Yeung
SPSatish K. Pillai
Satish K. Pillai
LNLishomwa Ndhlovu
Lishomwa Ndhlovu